| Nov 19 |
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
|
| Nov 10 |
Aligos Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations
|
| Nov 6 |
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
Aligos Therapeutics files $400M mixed securities shelf
|
| Nov 6 |
Aligos Therapeutics EPS of -$3.07 misses by $1.75
|
| Nov 6 |
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
|
| Oct 30 |
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
|
| Oct 15 |
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
|
| Sep 30 |
Aligos Therapeutics to Present at Investor Conferences in October
|
| Sep 24 |
Aligos Therapeutics names Hardean Achneck as chief medical officer
|
